Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear skin, according to an interim analysis of a phase 3 trial.
The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.
Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
GlobalData on MSN6d
Alumis and Kaken sign agreement in Japan to develop ESK-001Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback